Those who took weekly semaglutide had a 20 percent lower risk of serious heart events like heart attacks and strokes compared to those who did not
Emotional wellbeing, stigma, and why information alone isn't enough The importance of person-first language and the Language Matters movement The urgent need for diabetes psychology services in Ireland Why research and real-world data are essential to improving care Advances in pregnancy care, CGM access, and gestational diabetes support The growing role of AI in diabetes education, documentation, and clinical decision-making Progress on insulin pump access and technology adoption across Ireland Featured guests include Sinead Powell, Cathy Breen, Kate Gajewska, Fidelma Dunne, Christine Newman, Prof Derek O'Keeffe, and Tomas Patrick Griffin
The clinical trial for semaglutide is registered with ClinicalTrials.gov under the identifier NCT03693430.
doi: 10.1002/mc.22665 111 LagaMCottynAVan HerrewegheFVanden BergheWHaegemanGVan OostveldtPet al
